The most powerful
biomarker discovery platform
GEMMAai™
GEnoMic Marker Analyzer
AI-Powered platform for matching patients with right treatment
GEMMAai for clinical trial enrolment – available *
GEMMAai for companion diagnostics development – available *
GEMMAai for patients coming soon – pipeline *
TUMOR
TYPE
TUMOR GENOMES
TARGETED THERAPY
DISCOVERY
PROTOTYPE ASSAY
ANALITYCAL VALIDATION
CLINICAL VALIDATION
REGULATORY APPROVAL
UPCOMING
MILESTONES
BREAST
2152
CDK4/6i
Ant-HER2
PARPi
mTORi
PIK3i
2 analytically validated diagnostic tools in Q1 2021
OVARIAN
512
Carboplatin / PARPi
FDA breakthrough device submission Q2 2021
FASETM
GENOMIC FEATURE DATABASE
YOUR inhibitor
Discovery and validation
AI-POWERED
STRATIFICATION DIAGNOSTIC TOOL
Learn more
* For Research Use Only. Not for use in diagnostic procedures.
TUMOR TYPE: OVARIAN
WGS DATA
512
TARGETTED THERAPY
UPCOMING MILESTONES
FDA breakthrough device in Q3 2021
TUMOR TYPE: BREAST
WGS DATA
2152
TARGETTED THERAPY
UPCOMING MILESTONES
2 analytically validated diagnostic tools in Q1 2021
TUMOR TYPE: LUNG
WGS DATA
1852
TARGETTED THERAPY
UPCOMING MILESTONES
2 prototype assays in Q3 2021
FUSETM
WGS DATA
GENOMIC FEATURE DATABASE
TARGETTED THERAPY
YOUR inhibitor
DISCOVERY AND VALIDATION
AI-POWERED STRATIFICATION DIAGNOSTIC TOOL
News
IV Krajowa Naukowo-Szkoleniowa Konferencja Biobanków Polskich
W dniach 6-7 grudnia 2021 roku odbyła się IV Krajowa Naukowo-Szkoleniowa Konferencja Biobanków Polskich. Wydarzenie miało na celu prezentację osiągnięć polskiego środowiska biobankowego i podsumowanie pięciu lat członkostwa Polski w…
Read More
BiO€QUITY Europe on 17-19 May 2021
MNM Diagnostics has developed a unique AI-powered platform allowing for the rapid development of genome-based biomarkers providing an accurate prediction of the treatment outcomes for cancer patients. To date, we…
Read More
Certificate of Approval ISO 9001:2015
MNM Diagnostics received Certificate of Approval to the standards ISO 9001:2015, which means we meet requirements of the management standards in the organization in the field of : "Banking and…
Read More
The success of Polish scientists. Research on COVID-19 has been recognized as one of the most remarkable discoveries in 2020 by Nature
Research indicating the genetic background of the severe illness in COVID-19 cases, co-authored by Dr. Paweł Zawadzki from MNM Diagnostics and the Polish Biobanking Center, was among the most remarkable…
Read More
Our publications
A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers
The First Report of Biallelic Missense Mutations in the SFRP4 Gene Causing Pyle Disease in Two Siblings
A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection
Partners
Masz pytania lub wątpliwości?
